Grant Dorsey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grant Dorsey has a total of 573 co-authors. Here are the top co-authors by number of shared publications:
- Moses Robert Kamya
School of Medicine, Makerere University, Kampala, Uganda
53 shared publications - Philip Rosenthal
UCSF
32 shared publications - Bryan Greenhouse
Department of Medicine, University of California, San Francisco, USA
31 shared publications - Prasanna Jagannathan
Stanford University
28 shared publications - Joaniter Immaculate Nankabirwa
Infectious Diseases Research Collaboration , Kampala
25 shared publications - Emmanuel Arinaitwe
Infectious Diseases Research Collaboration, Uganda
23 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Malaria Journal
Maternal malaria and early-life infections shape humoral immunity to P. falciparum in infants
Maternally derived antibodies transferred across the placenta are hypothesized to protect infants against Plasmodium falciparum malaria in early life, but placental malaria may impair this transfer and alter the subsequent development of infant immunity. To test whether maternally derived and infant antibody responses are associated with protection from infection and clinical malaria, and how malaria exposure during pregnancy and infancy shapes these responses, we enrolled a birth cohort of infants in a birth cohort nested within a randomized trial of chemoprevention in Tororo, Uganda. We measured P. falciparum -specific antibody responses to 20 P. falciparum antigens and tetanus toxoid in 183 infants at birth, 6, and 12 months of age using a Luminex multiplex bead array. We also assessed the frequency and phenotype of peripheral T follicular helper cells and B cells using flow cytometry at 12 months of age. Placental malaria was associated with lower cord-blood antibody levels to tetanus toxoid (Benjamini-Hochberg [BH]-adjusted P = 0.0069), GEXP, HYP2 and SEA (BH-adjusted P = 0.05–0.1), and with higher levels to AMA1, while higher gestational age correlated with higher levels of antibodies to GEXP (BH-adjusted P = 0.033) and, more weakly, AMA1, GLURP, HSP40 and HYP2 (BH-adjusted P = 0.075). The maternal antibodies we measured in cord blood were not associated with protection in the first year of life, and neither was maternal malaria status. Infants generated antibodies against P. falciparum antigens in response to infection: levels of antibodies to ETRAMP5, GLURP, HYP2 and SBP1 were significantly higher in children with more parasitemic months in the preceding 6 months (BH-adjusted P < 0.05). No antibody, and no aggregate measure of repertoire breadth, was associated with subsequent protection. Interestingly, the number of parasitemic months in the first 6 months of life correlated with significantly decreased levels of antibodies to EBA140, H103, RH2 and RH4 at 1 year of age (BH-adjusted P < 0.05), whereas the number of symptomatic malaria episodes in that window was not. Early-life infections were not clearly associated with circulating follicular T cell or B cell phenotypic composition. These data suggest the infant antibody responses measured here are markers of exposure rather than correlates of protection against clinical malaria or parasitemia in the first year of life.
- 12 November 2026
- Published by Springer Nature in Malaria Journal
Open AccessMaternal malaria and early-life infections shape humoral immunity to P. falciparum in infants
Maternally derived antibodies transferred across the placenta are hypothesized to protect infants against Plasmodium falciparum malaria in early life, but placental malaria may impair this transfer and alter the subsequent development of infant immunity. To test whether maternally derived and infant antibody responses are associated with protection from infection and clinical malaria, and how malaria exposure during pregnancy and infancy shapes these responses, we enrolled a birth cohort of infants in a birth cohort nested within a randomized trial of chemoprevention in Tororo, Uganda. We measured P. falciparum -specific antibody responses to 20 P. falciparum antigens and tetanus toxoid in 183 infants at birth, 6, and 12 months of age using a Luminex multiplex bead array. We also assessed the frequency and phenotype of peripheral T follicular helper cells and B cells using flow cytometry at 12 months of age. Placental malaria was associated with lower cord-blood antibody levels to tetanus toxoid (Benjamini-Hochberg [BH]-adjusted P = 0.0069), GEXP, HYP2 and SEA (BH-adjusted P = 0.05–0.1), and with higher levels to AMA1, while higher gestational age correlated with higher levels of antibodies to GEXP (BH-adjusted P = 0.033) and, more weakly, AMA1, GLURP, HSP40 and HYP2 (BH-adjusted P = 0.075). The maternal antibodies we measured in cord blood were not associated with protection in the first year of life, and neither was maternal malaria status. Infants generated antibodies against P. falciparum antigens in response to infection: levels of antibodies to ETRAMP5, GLURP, HYP2 and SBP1 were significantly higher in children with more parasitemic months in the preceding 6 months (BH-adjusted P < 0.05). No antibody, and no aggregate measure of repertoire breadth, was associated with subsequent protection. Interestingly, the number of parasitemic months in the first 6 months of life correlated with significantly decreased levels of antibodies to EBA140, H103, RH2 and RH4 at 1 year of age (BH-adjusted P < 0.05), whereas the number of symptomatic malaria episodes in that window was not. Early-life infections were not clearly associated with circulating follicular T cell or B cell phenotypic composition. These data suggest the infant antibody responses measured here are markers of exposure rather than correlates of protection against clinical malaria or parasitemia in the first year of life.
- Open Access
Whole-genome characterization of Plasmodium falciparum population structure and drug resistance across Uganda and neighboring countries
Uganda has one of the world’s highest malaria burdens, but parasite population structure and connectivity have not been characterized nationally with whole-genome data. We analyzed 249 monoclonal Plasmodium falciparum genomes from 26 sentinel sites across Uganda in 2023 and compared them with publicly available genomes from five neighboring countries. Genetic diversity was high and differentiation low in Uganda, but identity-by-descent detected limited structure. This was most pronounced in the low-transmission southwest, where parasites shared ancestry and recent relatedness with isolates from western Tanzania. Selection scans identified signals at loci associated with resistance to artemisinins and their partner drugs, and to chloroquine and antifolates. The strongest signal was at PfPX1 where the PIN haplotype (L1222P, M1701I, D1705N) reached 70% prevalence nationwide, but selection was carried by PIN haplotypes that had additionally acquired D384A, largely confined to northern and eastern Uganda. A second substitution at the same codon, D384Y, formed a haplotype shared across the Tanzanian border. PfKelch13 variants were partitioned across multiple backgrounds, consistent with repeated independent emergence, and C469Y was enriched on the PfPX1 D384A-PIN background. These genomes provide a 2023 baseline for tracking potential mediators of drug resistance and support coordinated genomic surveillance across Uganda and its neighbors.
Open AccessWhole-genome characterization of Plasmodium falciparum population structure and drug resistance across Uganda and neighboring countries
Uganda has one of the world’s highest malaria burdens, but parasite population structure and connectivity have not been characterized nationally with whole-genome data. We analyzed 249 monoclonal Plasmodium falciparum genomes from 26 sentinel sites across Uganda in 2023 and compared them with publicly available genomes from five neighboring countries. Genetic diversity was high and differentiation low in Uganda, but identity-by-descent detected limited structure. This was most pronounced in the low-transmission southwest, where parasites shared ancestry and recent relatedness with isolates from western Tanzania. Selection scans identified signals at loci associated with resistance to artemisinins and their partner drugs, and to chloroquine and antifolates. The strongest signal was at PfPX1 where the PIN haplotype (L1222P, M1701I, D1705N) reached 70% prevalence nationwide, but selection was carried by PIN haplotypes that had additionally acquired D384A, largely confined to northern and eastern Uganda. A second substitution at the same codon, D384Y, formed a haplotype shared across the Tanzanian border. PfKelch13 variants were partitioned across multiple backgrounds, consistent with repeated independent emergence, and C469Y was enriched on the PfPX1 D384A-PIN background. These genomes provide a 2023 baseline for tracking potential mediators of drug resistance and support coordinated genomic surveillance across Uganda and its neighbors.
- Open Access
- 28 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Low Birthweight and Prematurity, but not Malaria Chemoprevention, Are Associated With Reduced Pneumococcal Vaccine Immunogenicity in Ugandan Infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8- and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (ie, seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention, and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500 g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43–94%] antibody fold-change, P = .003) and reduced odds of seroconversion (OR = 0.19 [95% CI: 0.06–0.57], P = .003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24–94%] antibody fold-change, P = .018; OR = 0.181 [95% CI: 0.05–0.65], P = .009). Conclusions: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
- 28 September 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessLow Birthweight and Prematurity, but not Malaria Chemoprevention, Are Associated With Reduced Pneumococcal Vaccine Immunogenicity in Ugandan Infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial (NCT04978272) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log10 fold-change in IgG concentration between the 8- and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (ie, seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention, and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500 g) was associated with lower immunogenicity (82% lower [95% confidence interval (CI): 43–94%] antibody fold-change, P = .003) and reduced odds of seroconversion (OR = 0.19 [95% CI: 0.06–0.57], P = .003); preterm birth (<37 weeks) showed similar associations (79% lower [95% CI: 24–94%] antibody fold-change, P = .018; OR = 0.181 [95% CI: 0.05–0.65], P = .009). Conclusions: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
- Open Access
- 5 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Prevalence of Congenital Cytomegalovirus Infection in a CMV-Endemic Ugandan Population
Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood deafness and disability worldwide. However, less is known about its epidemiology in low-income regions where most women are CMV-seropositive at conception. We found that cCMV is highly prevalent in rural Uganda (3.73%) and is associated with lower gravidity and placental malaria. We additionally report a high transmission intensity in the first years of life, with 97.3% of children acquiring CMV IgG by age 3.
- 5 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessPrevalence of Congenital Cytomegalovirus Infection in a CMV-Endemic Ugandan Population
Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood deafness and disability worldwide. However, less is known about its epidemiology in low-income regions where most women are CMV-seropositive at conception. We found that cCMV is highly prevalent in rural Uganda (3.73%) and is associated with lower gravidity and placental malaria. We additionally report a high transmission intensity in the first years of life, with 97.3% of children acquiring CMV IgG by age 3.
- Open Access
- 12 August 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (8) , e0005951
Imported malaria predominates in near-elimination settings in Southwestern Uganda
Malaria transmission in southwestern Uganda is low, but persists despite control efforts. Identifying whether infections are locally sustained or imported by travelers is critical for guiding interventions. We integrated epidemiologic surveillance with parasite genomics to characterize imported malaria episodes at three health facilities in southwestern Uganda. Between January 2023 and June 2024, we enrolled microscopy-confirmed malaria cases at three health facilities, Maziba and Muko (very low transmission) and Kamwezi (low-to-moderate transmission), administered travel history questionnaires, and collected dried blood spots for genotyping. 348 Plasmodium falciparum infections were genotyped using MAD 4 HatTeR, a multiplex amplicon sequencing panel targeting 165 diversity markers and 38 drug resistance loci. Complexity of infection and pairwise relatedness were estimated using MOIRE and Dcifer, respectively. Plasmotrack, a transmission network framework, was used to infer transmission networks and importation rates. Amongst malaria cases, travel was common in Maziba (87%) and Muko (96%) but infrequent in Kamwezi (12%). Most travel in Maziba and Muko was from high-transmission regions in northern and eastern Uganda. Parasites in Maziba and Muko exhibited higher within-host diversity and lower within-site relatedness compared to those in Kamwezi, with the proportion of significant related infection pairs substantially lower in Maziba (0.59%) and Muko (0.17%) than in Kamwezi (6.36%). Transmission network inference identified most infections in Maziba and Muko as imported, with the majority of inferred secondary transmission linked to recent travelers. In contrast, Kamwezi showed multiple highly related clusters, indicating sustained local transmission. Validated markers of artemisinin resistance (K13 P441L and R561H) were more prevalent in Kamwezi. Malaria in Maziba and Muko was driven largely by importation from other parts of Uganda, while local transmission predominated in Kamwezi. Tailored interventions addressing travel-associated risks and local transmission, supported by travel histories and genetic data will be valuable to advance malaria elimination in this region.
- 12 August 2026
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 6 (8) , e0005951
Open AccessImported malaria predominates in near-elimination settings in Southwestern Uganda
Malaria transmission in southwestern Uganda is low, but persists despite control efforts. Identifying whether infections are locally sustained or imported by travelers is critical for guiding interventions. We integrated epidemiologic surveillance with parasite genomics to characterize imported malaria episodes at three health facilities in southwestern Uganda. Between January 2023 and June 2024, we enrolled microscopy-confirmed malaria cases at three health facilities, Maziba and Muko (very low transmission) and Kamwezi (low-to-moderate transmission), administered travel history questionnaires, and collected dried blood spots for genotyping. 348 Plasmodium falciparum infections were genotyped using MAD 4 HatTeR, a multiplex amplicon sequencing panel targeting 165 diversity markers and 38 drug resistance loci. Complexity of infection and pairwise relatedness were estimated using MOIRE and Dcifer, respectively. Plasmotrack, a transmission network framework, was used to infer transmission networks and importation rates. Amongst malaria cases, travel was common in Maziba (87%) and Muko (96%) but infrequent in Kamwezi (12%). Most travel in Maziba and Muko was from high-transmission regions in northern and eastern Uganda. Parasites in Maziba and Muko exhibited higher within-host diversity and lower within-site relatedness compared to those in Kamwezi, with the proportion of significant related infection pairs substantially lower in Maziba (0.59%) and Muko (0.17%) than in Kamwezi (6.36%). Transmission network inference identified most infections in Maziba and Muko as imported, with the majority of inferred secondary transmission linked to recent travelers. In contrast, Kamwezi showed multiple highly related clusters, indicating sustained local transmission. Validated markers of artemisinin resistance (K13 P441L and R561H) were more prevalent in Kamwezi. Malaria in Maziba and Muko was driven largely by importation from other parts of Uganda, while local transmission predominated in Kamwezi. Tailored interventions addressing travel-associated risks and local transmission, supported by travel histories and genetic data will be valuable to advance malaria elimination in this region.
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
The Value of Ultrasound in Improving Gestational Age Estimates and Impact on Accuracy of Maternal-Child Health Metrics in Rural Uganda
Background: In resource-limited settings, pregnancy dating often relies on the last menstrual period (LMP). Gestational age (GA) is best confirmed by ultrasound. The value of ultrasound for improving population-level maternal health indicators remains understudied.Methods: This was a cohort study of 2,757 pregnant women enrolled in a trial comparing intermittent preventative treatments for malaria. Ultrasound was performed between 12–20 weeks gestation to confirm GA. Final estimated due date (F-EDD) was determined using established standards to assess discordance between LMP-based (LMP-EDD) and ultrasound-based (US-EDD) EDD. We compared LMP-EDD with F-EDD for estimating preterm birth (PTB) and small for gestational age (SGA) prevalence.Results: Among 2,757 participants, 1,566 (56 8%) had unknown LMP and were dated by ultrasound. Among 1,191 with known LMP, 253 (21 2%) were redated by ultrasound, of whom 229 had live births. PTB prevalence was higher using LMP-EDD than F-EDD (7 3% vs 5 2%, p=<0 001). SGA prevalence did not differ significantly (22% vs. 23 1%, p=0.05). Among participants with LMP-EDD redated by ultrasound, prevalence of PTB was overestimated nearly fourfold by LMP compared to ultrasound (13 1% vs. 3 5%, p=<0 001); SGA rates were similar (17 9% vs. 23 1%, p=0 05).Interpretation: Reliance on LMP-EDD overestimated PTB prevalence, underscoring the value of ultrasound for accurate maternal health surveillance.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Value of Ultrasound in Improving Gestational Age Estimates and Impact on Accuracy of Maternal-Child Health Metrics in Rural Uganda
Background: In resource-limited settings, pregnancy dating often relies on the last menstrual period (LMP). Gestational age (GA) is best confirmed by ultrasound. The value of ultrasound for improving population-level maternal health indicators remains understudied.Methods: This was a cohort study of 2,757 pregnant women enrolled in a trial comparing intermittent preventative treatments for malaria. Ultrasound was performed between 12–20 weeks gestation to confirm GA. Final estimated due date (F-EDD) was determined using established standards to assess discordance between LMP-based (LMP-EDD) and ultrasound-based (US-EDD) EDD. We compared LMP-EDD with F-EDD for estimating preterm birth (PTB) and small for gestational age (SGA) prevalence.Results: Among 2,757 participants, 1,566 (56 8%) had unknown LMP and were dated by ultrasound. Among 1,191 with known LMP, 253 (21 2%) were redated by ultrasound, of whom 229 had live births. PTB prevalence was higher using LMP-EDD than F-EDD (7 3% vs 5 2%, p=<0 001). SGA prevalence did not differ significantly (22% vs. 23 1%, p=0.05). Among participants with LMP-EDD redated by ultrasound, prevalence of PTB was overestimated nearly fourfold by LMP compared to ultrasound (13 1% vs. 3 5%, p=<0 001); SGA rates were similar (17 9% vs. 23 1%, p=0 05).Interpretation: Reliance on LMP-EDD overestimated PTB prevalence, underscoring the value of ultrasound for accurate maternal health surveillance.
- Open Access
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0036126
Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024
The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
- 15 June 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0036126
Open AccessSustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024
The emergence and spread of drug resistance threaten malaria control in Uganda. This study reports new data on key polymorphisms associated with antimalarial drug sensitivity at 32 malaria reference centers in Uganda in 2023 and 2024. Ten thousand thirty samples were collected from patients aged >6 months presenting with uncomplicated falciparum malaria and sequenced using the MAD 4 HatTeR panel and Illumina platforms; of these, 8,518 passed quality control and were analyzed. Multiple validated or candidate K13 mutations associated with artemisinin partial resistance were detected at ≥20% prevalence at one or more sites across multiple timepoints. The K13 mutations A675V and C469Y predominated in northern Uganda, P441L was most common in western Uganda, and R561H and C469F were confined to southwestern Uganda. After rapid increases in earlier years, prevalences of K13 mutations plateaued at most sites, with A675V, C469Y, and P441L reaching maximum site prevalences of 40%, 58%, and 46%, respectively. Prevalence of the chloroquine resistance marker CRT K76T was generally low but increased substantially at three sites in northwestern Uganda, rising to 38% at the last timepoint, with CRT H97L, newly reported in Africa, following a similar trend. The antifolate resistance quintuple mutant haplotype remained highly prevalent nationwide. In addition, DHPS A581G and DHFR I164L, markers of higher-level antifolate resistance, were most common in southwestern Uganda with prevalences up to 64% and 76%, respectively; DHFR I164L also expanded into central and eastern regions. These results highlight continued geographic heterogeneity and underscore the need for continued, nationwide molecular surveillance to guide treatment and chemoprevention policies.
- Open Access
- 7 June 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Congenital cytomegalovirus infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors
Gamma delta (γδ) T cells emerge early during human gestation and are uniquely equipped to protect the fetus and infant following infection, due to their innate-like recognition of conserved molecular ligands. Following congenital cytomegalovirus infection (cCMV), Vδ1 T cells have been shown to expand, differentiate, and upregulate cytotoxic mediators, but display markedly restricted γδTCR diversity compared to CMV-infected adults. Early fetal γδ T cells are biased toward rapid effector function and comprise a distinct ontological “layer” that can be distinguished from late gestation γδ T cells based on TCR characteristics. To better understand the contribution of fetal γδ T cells to antiviral defense in utero, we analyzed γδ T cells from cCMV+ and uninfected neonates in Uganda using flow cytometry and paired single-cell RNA and TCR sequencing. We observed that in cCMV+ neonates, γδ T cells clonally proliferate and differentiate into a uniform population of cytotoxic effectors. The expanded Vδ1 population is comprised of diverse clonotypes with broad Vγ chain usage, with a striking correlation between expansion and publicity. Overall, γδTCR repertoires of cCMV+ infants have shorter CDR3 lengths and fewer N additions, suggesting they derive from early fetal progenitor cells. In cCMV+ infants, most cells with fetal γδTCR characteristics are effector-differentiated, whereas in uninfected infants, such cells are rare and predominantly naïve. Together, these findings demonstrate that cCMV infection drives an oligoclonal expansion of highly cytotoxic effector γδ T cells with fetal-like TCR features, illustrating how the developing immune system prioritizes broad reactivity and rapid effector function over specificity.
- 7 June 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Open AccessCongenital cytomegalovirus infection drives oligoclonal expansion of cytotoxic γδ T cells from early fetal progenitors
Gamma delta (γδ) T cells emerge early during human gestation and are uniquely equipped to protect the fetus and infant following infection, due to their innate-like recognition of conserved molecular ligands. Following congenital cytomegalovirus infection (cCMV), Vδ1 T cells have been shown to expand, differentiate, and upregulate cytotoxic mediators, but display markedly restricted γδTCR diversity compared to CMV-infected adults. Early fetal γδ T cells are biased toward rapid effector function and comprise a distinct ontological “layer” that can be distinguished from late gestation γδ T cells based on TCR characteristics. To better understand the contribution of fetal γδ T cells to antiviral defense in utero, we analyzed γδ T cells from cCMV+ and uninfected neonates in Uganda using flow cytometry and paired single-cell RNA and TCR sequencing. We observed that in cCMV+ neonates, γδ T cells clonally proliferate and differentiate into a uniform population of cytotoxic effectors. The expanded Vδ1 population is comprised of diverse clonotypes with broad Vγ chain usage, with a striking correlation between expansion and publicity. Overall, γδTCR repertoires of cCMV+ infants have shorter CDR3 lengths and fewer N additions, suggesting they derive from early fetal progenitor cells. In cCMV+ infants, most cells with fetal γδTCR characteristics are effector-differentiated, whereas in uninfected infants, such cells are rare and predominantly naïve. Together, these findings demonstrate that cCMV infection drives an oligoclonal expansion of highly cytotoxic effector γδ T cells with fetal-like TCR features, illustrating how the developing immune system prioritizes broad reactivity and rapid effector function over specificity.
- Open Access
Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial ( NCT04978272 ) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log 10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19, p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower antibody fold-change, p=0.018; OR=0.181, p=0.009). Conclusion: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
Open AccessLow birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants
Background: Malaria exposure has been hypothesized to alter immune responses to childhood vaccines, but evidence is inconsistent. We evaluated whether early-life malaria exposure and perennial malaria chemoprevention (PMC) modify antibody responses to the 10-valent pneumococcal conjugate vaccine (PCV-10) among infants in a high malaria transmission setting in eastern Uganda. Methods: This study was nested within the MIC-DroP trial ( NCT04978272 ) whereby 202 infants were selected for inclusion. Serotype-specific IgG concentrations were measured using an in-house multiplex seroassay from samples obtained at 8 and 24 weeks of age. Immunogenicity was quantified as the log 10 fold-change in IgG concentration between the 8 and 24-week timepoints, and seroconversion as ≥0.35 μg/mL at week 24 (i.e., seropositive). Generalized estimating equation models were used to assess associations of PCV-10 immunogenicity and seroconversion with malaria exposure, malaria chemoprevention and birth outcomes. Results: Among the 195 of 202 infants who completed the three-dose PCV-10 series, neither infant PMC nor malaria exposure from study enrollment to 14 weeks were associated with PCV-10 immunogenicity or seroconversion. In contrast, low birthweight (<2500g) was associated with lower immunogenicity (82% lower antibody fold-change, p=0.003) and reduced odds of seroconversion (OR=0.19, p=0.003); preterm birth (<37 weeks) showed similar associations (79% lower antibody fold-change, p=0.018; OR=0.181, p=0.009). Conclusion: In this malaria-endemic setting, early-life malaria exposure and chemoprevention did not measurably alter PCV-10 antibody responses. However, low birthweight and prematurity were associated with reduced vaccine immunogenicity.
- Open Access
- 6 May 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 114 (5) , 905-912
Natural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda
: Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.
- 6 May 2026
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 114 (5) , 905-912
Open AccessNatural History and the Burden of Malaria During the First Year of Life in the High-Transmission Setting of Uganda
: Infants under 1 year of age are considered partially protected from malaria because of maternal antibodies and fetal hemoglobin. However, emerging evidence suggests that the malaria burden in this age group may be underestimated. A cohort of 855 infants in Busia District, Uganda, was enrolled in the present study to characterize malaria incidence and parasite prevalence during the first year of life and to identify risk factors for these outcomes. The study was conducted from 2021 to 2025, before the malaria vaccine roll-out. Infants born to HIV-uninfected women were enrolled at 4–8 weeks of age and followed by active and passive case detection to 1 year of age in a dedicated study clinic that is open 7 days/week. Routine visits every 4 weeks included assessments for parasitemia via microscopy and quantitative polymerase chain reaction testing. Over 706.7 person-years of follow-up, 662 malaria episodes occurred. The overall prevalence of microscopic parasitemia was 7.9%, and the combined prevalence of microscopic and submicroscopic parasitemia was 21.8%. Sickle cell trait (Hemoglobin AS) conferred 39% protection against symptomatic malaria but was not associated with the risk of parasitemia. Modern housing construction and higher maternal education were independently associated with reduced malaria risk. District-wide distribution of long-lasting insecticide-treated nets containing alpha–cypermethrin plus chlorfenapyr in October 2023 was followed by an 80% reduction in malaria incidence and significant declines in parasitemia prevalence. These findings underscore the urgent need for age-appropriate preventative interventions targeting young infants, such as earlier vaccine administration or treatment with monoclonal antibodies, alongside sustained investment in next-generation vector control and attention to socioeconomic determinants of malaria risk.